Patients with symptomatic multiple myeloma (MM) following induction and conditioning therapy and autologous stem cell transplant (ASCT) may derive survival benefit from maintenance therapy with ixazomib, according to the phase III TOURMALINE-MM3* trial.
The addition of daratumumab to lenalidomide and dexamethasone improved progression-free survival (PFS) in patients newly diagnosed with multiple myeloma (MM) who were ineligible for a stem cell transplant, according to interim results of the phase III multinational MAIA* trial.
Bortezomib in combination with thalidomide plus dexamethasone (VTD) significantly improves progression-free survival (PFS) and overall survival (OS) vs thalidomide plus dexamethasone (TD) alone in patients with newly diagnosed multiple myeloma (MM) undergoing double autologous stem cell transplantation (ASCT), 10-year results of the GIMEMA-MMY-3006 trial have shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
intensity is significantly associated with increased relapse, decreased
disease-free survival (DFS), and decreased overall survival (OS) in acute
myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new
analysis of a phase III randomized clinical trial has shown.